![]() And patients are, again, caught in the middle. It’s the latest twist in a long-running dispute between the drug industry and insurers over which group is more to blame for rising costs to patients. But some benefit brokers and companies like SaveOnSP say they can help trim employers’ spending on insurance - which, they say, could be the difference between an employer offering coverage to workers or not. Drugmakers object, saying the money was intended primarily for patients. Now, though, employers, or the vendors and insurers they hire specifically to oversee such efforts, are seeking that money to offset their own costs. Those employers are tapping into dollars provided through programs they have previously criticized: patient financial assistance initiatives set up by drugmakers, which some benefit managers have complained encourage patients to stay on expensive brand-name drugs when less expensive options might be available. ![]() Sutton had unwittingly become part of a strategy that employers are using to deal with the high cost of drugs prescribed to treat conditions such as arthritis, psoriasis, cancer, and hemophilia. She added that “every single FDA-approved medication for juvenile arthritis” was on the list of nonessential benefits. “It really gave us no choice,” said Sutton, of Woodinville, Washington. The July 2021 letter said the family could either participate in a new effort overseen by a company called SaveOnSP and get the drug free of charge or be saddled with a monthly copayment that could top $1,000. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |